. Author manuscript; available in PMC: 2016 Mar 15.

Published in final edited form as: Clin Cancer Res. 2015 Jan 14;21(6):1429–1437. doi: 10.1158/1078-0432.CCR-14-2083

Table 5.

Crude and adjusted association between tumor marker positivity and 2-year overall mortality DLBCL patients by HIV infection status

Tumor marker positivity	HIV-infected patients		HIV-uninfected patients
	Bivariate analyses (crude)
	OR (95% CI)	P	OR (95% CI)	P
cMYC	2.36 (0.87–6.42)	0.09	2.05 (0.61–6.90)	0.25
P27	1.61 (0.63–4.10)	0.32	0.72 (0.19–2.65)	0.62
BCL6	0.45 (0.18–1.15)	0.10	—^a
PKC-β2	0.86 (0.34–2.19)	0.75	11.58 (0.97–138.76)	0.05
MUM1	1.63 (0.65–4.07)	0.30	2.10 (0.48–9.30)	0.33
CD44	0.32 (0.08–1.27)	0.11	1.98 (0.55–7.09)	0.29
	Multivariable analyses (adjusted)^b
cMYC	3.09 (0.90–10.55)	0.07	2.84 (0.54–15.01)	0.22
P27	1.44 (0.49–4.22)	0.50	0.18 (0.03–1.27)	0.08
BCL6	0.48 (0.12–1.87)	0.29	—^a
PKC-β2	0.54 (0.17–1.69)	0.29	3.93 (0.19–83.28)	0.38
MUM1	0.90 (0.29–2.79)	0.85	0.80 (0.10–6.54)	0.83
CD44	0.18 (0.04–0.89)	0.04	1.52 (0.28–8.25)	0.63

OR cannot be estimated due to rare marker expression.

Model adjusted for IPI, germinal center phenotype, DLBCL subtype, and receipt of chemotherapy. Gender and race were matched and thus did not require adjustment in the multivariable model.